CuraGen Corp. (CRGN) announced that it has commenced the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study.
The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every 3 weeks to patients with locally advanced or metastatic breast cancer who have received prior therapy. The study would enroll up to about 40 patients to confirm the maximum tolerated dose and to assess efficacy using a Simon 2-Stage design with an endpoint of progression-free rate at 12 weeks, the company said.
For comments and feedback: editorial@rttnews.com